Capital Research Global Investors’s BridgeBio Pharma BBIO Stock Holding History

Capital Research Global Investors’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$52.1M	Sell	700,107 -63,595	-8%	-$4.45M	0.01%	342
2026 Q1	$56.7M	Sell	763,702 -1,170,996	-61%	-$84.9M	0.01%	347
2025 Q4	$148M	Buy	1,934,698 +1,572	+0.1%	+$103K	0.03%	267
2025 Q3	$100M	Sell	1,933,126 -2,055,172	-52%	-$100M	0.02%	292
2025 Q2	$172M	Sell	3,988,298 -679,104	-15%	-$24.7M	0.03%	235
2025 Q1	$161M	Buy	4,667,402 +1,140,655	+32%	+$38.5M	0.04%	243
2024 Q4	$96.8M	Buy	3,526,747 +912,439	+35%	+$23.6M	0.02%	304
2024 Q3	$66.6M	Buy	2,614,308 +402,223	+18%	+$10.6M	0.01%	316
2024 Q2	$56M	Hold	2,212,085	–	–	0.01%	326
2024 Q1	$68.4M	Buy	2,212,085 +1,111,975	+101%	+$37.8M	0.02%	318
2023 Q4	$44.4M	Hold	1,100,110	–	–	0.01%	329
2023 Q3	$27.6M	Buy	+1,100,110	New	+$31.2M	0.01%	358

Other funds holding BBIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital Research Global Investors's BBIO Position: Q2 2026 in Review

Capital Research Global Investors reduced its BridgeBio Pharma (BBIO) stake by 8.3% in Q2 2026, selling an estimated $4.45M and leaving 700,107 shares worth $52.1M. The position accounts for 0.01% of the portfolio, ranked #342.

Capital Research Global Investors first reported a position in BBIO in Q3 2023 and has held it in 12 quarters since. The position peaked at $172M in Q2 2025. 329 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Capital Research Global Investors held 700,107 shares of BridgeBio Pharma worth $52.1M as of Q2 2026.
Capital Research Global Investors sold 63,595 BridgeBio Pharma shares in Q2 2026, an estimated $4.45M.
BridgeBio Pharma made up 0.01% of Capital Research Global Investors's portfolio in Q2 2026, its #342 holding.
Capital Research Global Investors first reported a position in BridgeBio Pharma in Q3 2023 and has held it in 12 quarters since.
Capital Research Global Investors's BridgeBio Pharma position peaked at $172M in Q2 2025.
329 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Capital Research Global Investors's 13F filing for Q2 2026, filed 12 Aug 2026.